- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04365400
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)
A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomised, double-blind, Placebo-controlled, 3-arm, multi-centre Phase IIb study consisting of 26 weeks of active treatment and a 2-week post-treatment follow-up period in adult patients with hypertriglyceridemia and concomitant type 2 diabetes.
The screening period consisted of up to 6-weeks lead-in during which all patients were to undergo diet and lifestyle stabilisation, washout of disallowed medications and optimisation of statins.
After screening, patients were randomised (1:1:1) at the baseline visit into the following treatment groups:
- Treatment Group A (Placebo): four Placebo capsules orally administered twice a day, i.e., eight capsules daily for 26 weeks.
- Treatment Group B (Epeleuton 2g): two Epeleuton 500 mg capsules and two Placebo capsules orally administered twice a day, i.e., eight capsules daily for 26 weeks.
- Treatment Group C (Epeleuton 4g): four Epeleuton 500 mg capsules orally administered twice a day, i.e., eight capsules daily for 26 weeks.
The observation period was 32-34 weeks (lead-in: 4-6 weeks, treatment duration: 26 weeks, follow-up period: 2 weeks). During the study, 10 visits to the clinic were scheduled: two screening visits (Visit 1 and Visit 2), one visit at the start of the comparative treatment period (baseline/Visit 3), six visits in the comparative treatment period (Visit 4/Week 4, Visit 5/Week 8, Visit 6/Week 12, Visit 7/Week 16, Visit 8/Week 20 and Visit 9/Week 26 or Early Termination) and one final safety follow-up visit (Visit 10/Week 28).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Batumi, Georgia
- Georgia Site 1
-
Kutaisi, Georgia
- Georgia Site 2
-
Kutaisi, Georgia
- Georgia Site 3
-
Tbilisi, Georgia
- Georgia Site 4
-
-
-
-
-
Dresden, Germany
- Germany Site 7
-
Hamburg, Germany
- Germany Site 3
-
Heidelberg, Germany
- Germany Site 1
-
Lübeck, Germany
- Germany Site 5
-
-
-
-
-
Herzliya, Israel
- Israel Site 9
-
H̱olon, Israel
- Israel Site 1
-
Jerusalem, Israel
- Israel Site 5
-
Jerusalem, Israel
- Israel Site 6
-
Nahariya, Israel
- Israel Site 4
-
Sakhnīn, Israel
- Israel Site 8
-
Tel Aviv, Israel
- Israel Site 2
-
Tel Aviv, Israel
- Israel Site 3
-
-
-
-
-
Ogre, Latvia
- Latvia Site 4
-
Riga, Latvia
- Latvia Site 1
-
Riga, Latvia
- Latvia Site 2
-
Riga, Latvia
- Latvia Site 3
-
-
-
-
-
Lausanne, Switzerland
- Switzerland Site 3
-
Luzern, Switzerland
- Switzerland Site 4
-
Olten, Switzerland
- Switzerland Site 2
-
Saint Gallen, Switzerland
- Switzerland Site 1
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72204
- US Site 5
-
-
California
-
Cerritos, California, United States, 90703
- US Site 23
-
Huntington Park, California, United States, 90255
- US Site 18
-
Los Angeles, California, United States, 90057
- US Site 19
-
Panorama City, California, United States, 91402
- US Site 20
-
Santa Ana, California, United States, 92704
- US Site 21
-
Santa Ana, California, United States, 92705
- US Site 13
-
-
Georgia
-
Adairsville, Georgia, United States, 30103
- US Site 15
-
-
Iowa
-
Ames, Iowa, United States, 50010
- US Site 35
-
-
New York
-
Albany, New York, United States, 12203
- US Site 2
-
-
North Carolina
-
Hickory, North Carolina, United States, 28601
- US Site 25
-
Morehead City, North Carolina, United States, 28557
- US Site 11
-
Raleigh, North Carolina, United States, 27609
- US Site 34
-
Rocky Mount, North Carolina, United States, 27804
- US Site 26
-
Salisbury, North Carolina, United States, 28144
- US Site 28
-
Statesville, North Carolina, United States, 28625
- US Site 32
-
Wilmington, North Carolina, United States, 28601
- US Site 27
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- US Site 22
-
-
Pennsylvania
-
Wyomissing, Pennsylvania, United States, 19610
- US Site 1
-
Yardley, Pennsylvania, United States, 19067
- US Site 3
-
-
Tennessee
-
Jackson, Tennessee, United States, 38301
- US Site 12
-
-
Texas
-
Dallas, Texas, United States, 75231
- US Site 7
-
Fort Worth, Texas, United States, 76107
- US Site 8
-
Fort Worth, Texas, United States, 76164
- US Site 14
-
Houston, Texas, United States, 77036
- US Site 24
-
Houston, Texas, United States, 77061
- US Site 30
-
Houston, Texas, United States, 77079
- US Site 6
-
Houston, Texas, United States, 77099
- US Site 33
-
Missouri City, Texas, United States, 77459
- US Site 29
-
North Richland Hills, Texas, United States, 76180
- US Site 31
-
Waco, Texas, United States, 76708
- US Site 10
-
-
Virginia
-
Winchester, Virginia, United States, 22601
- US Site 17
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients diagnosed with type 2 diabetes mellitus at least 90 days prior to the first screening visit.
- Patients with a HbA1C (glycosylated haemoglobin) between 7.0 - 10.0% (53-86 mmol/mol) (both inclusive)
Patients with a fasting triglyceride level ≥200 mg/dL (2.26 mmol/L) and <750mg/dL (8.46 mmol/L) at both screening visits.
Note: If the triglyceride level is outside the required range at the second screening visit, an additional measurement can be obtained 1 week later, to confirm eligibility.
Note: If a large difference in triglyceride level (>15%) is observed between screening 1 and screening 2, an additional measurement may be requested or patient may be deemed not eligible.
- Patients who have been educated regarding diet and exercise at or before visit 1 (screening 1) and are willing to maintain and not alter a stable diet and activity routine throughout the study.
Patients who have been on a stable statin therapy at doses that are likely to achieve optimal LDL cholesterol and who are willing to continue this treatment throughout the study.
Note: Stable statin therapy may consist of a statin with or without ezetimibe.
- Patients with an LDL cholesterol level <130mg/dL (3.34 mmol/L) at both screening visits.
- Patients who have a body mass index (BMI) ≥ 25kg/m2 and <50kg/m2.
Patients who have been on a stable daily dose of metformin (at least 1500mg or maximum tolerated dose for metformin monotherapy as documented in the subject medical record) and/or a sulfonylurea and/or a dipeptidyl peptidase-4 (DPP-4) inhibitor and/or a sodium-glucose transport protein 2 inhibitor (SGLT2i) and/or a GLP1-RA and/or basal insulin for at least 90 days prior to the day of first screening visit.
Note: Dose of GLP1-RA must be stable for 6 months prior to baseline with no weight change >2kg for 3 months prior to baseline.
Note: Dose of basal insulin must be stable for 4 months prior to baseline. All types of basal insulin are permitted, including insulin glargine, insulin degludec, insulin detemir, NPH insulin and pre-mixed insulin.
Female patients and male patients with female partners of childbearing potential must use highly effective contraceptive methods or have a sterilised partner for the duration of the study. Highly effective contraceptive methods are defined as methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include hormonal contraception, intrauterine device or sexual abstinence.
Note: A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
Note: Hormonal contraceptives must be on a stable dose for at least one month before baseline.
Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.
- Patients whose pre-study or screening clinical laboratory findings do not interfere with their participation in the study, in the opinion of the Investigator, and do not violate any inclusion or exclusion criteria
- Male or female patients aged 18 years and older on the day of signing the informed consent form (ICF).
- Patients who are able to communicate well with the Investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent prior to initiation of any study specific activities or procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DS102 2000mg
Participants in this group received 1000mg DS102 capsules twice daily.
|
DS102 Epeleuton capsules
Other Names:
|
Experimental: DS102 4000mg
Participants in this group received 2000mg DS102 capsules twice daily.
|
DS102 Epeleuton capsules
Other Names:
|
Placebo Comparator: Placebo
Participants in this group received placebo capsules twice daily.
|
Placebo capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Triglycerides From Baseline to Week 16
Time Frame: 16 weeks
|
Analysis of changes and percentage changes of triglycerides was performed using a Wilcoxon rank sum test with the Hodges Lehmann median and 95% confidence intervals estimates.
For analysis of triglycerides, baseline was defined as the mean of the Baseline (Visit 3) and Screening 2/Week -1 (Visit 2) measurements.
|
16 weeks
|
Change in HbA1c From Baseline to Week 26
Time Frame: 26 weeks
|
Changes from baseline of HbA1c at each visit were analysed using mixed model analysis of covariance (ANCOVA) with baseline value as a covariate.
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
% Change in Triglycerides From Baseline to Weeks 4, 8, 12, 20 and 26
Time Frame: 26 weeks
|
Percent change in triglycerides from baseline to weeks 4, 8, 12, 20 and 26
|
26 weeks
|
Change in HbA1c From Baseline to Weeks 4, 8, 12, 16 and 20
Time Frame: 20 weeks
|
Change in HbA1c (glycosylated haemoglobin) from baseline to weeks 4, 8, 12, 16 and 20
|
20 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Markus Weissbach, MD, Afimmune
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS102A-07-CV1
- 2020-000065-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States